<?xml version="1.0" encoding="UTF-8"?>
<p>Cyclin E/CDK2 complexation plays an important role at G1 phase, whereas, cyclin A/CDK2 complexation terminates S phase and drives the cell cycle through normal G2/M phase progression
 <xref rid="CIT0025" ref-type="bibr">
  <sup>25</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0037" ref-type="bibr">
  <sup>37</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0103" ref-type="bibr">
  <sup>103</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0104" ref-type="bibr">
  <sup>104</sup>
 </xref>. Furthermore, a significant percentage of CDK2-deficient cells arrest in the G2/M phase, additionally, breast cancer cells exposed to CDK2 inhibitors show G2/M phase arrest
 <xref rid="CIT0023" ref-type="bibr">
  <sup>23</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0105" ref-type="bibr">
  <sup>105</sup>
 </xref>. In the same vein, GSK-3β regulates the strength of the mitotic checkpoint and connects the PI3K and WNT-signalling pathways to mitosis, furthermore, GSK-3β inhibitors induce G2/M phase arrest as well
 <xref rid="CIT0030" ref-type="bibr">
  <sup>30</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0106" ref-type="bibr">
  <sup>106</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0107" ref-type="bibr">
  <sup>107</sup>
 </xref>.
</p>
